Orion Corporation and Alligator Bioscience announce immuno-oncology research collaboration and license agreement

NEXT STORY
Allarity Therapeutics Elaborates on the Contents of the Meeting Agenda for the Extraordinary General Meeting Announced on August 16, 2021
PREV STORY
H1 2021: Tecan reports substantial double-digit growth in sales and more than a doubling in net profit – on top of an already strong performance in the prior-year period
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Basilea berichtet auf ESMO-Meeting über klinischen Nutzen des Medikamentenkandidaten Derazantinib bei Patienten mit intrahepatischem Cholangio­karzinom (iCCA) und verschiedenen FGFR2-Genaberrationen

author_avatar
NASDAQ Market News

Plus Therapeutics Shareholder Update: Transition Achieved in 2019; Poised for Expansion in 2020

author_avatar
NASDAQ Market News

Rexahn Pharmaceuticals Announces Initiation of Phase Ib/IIa Clinical Trial of Its Novel Oral Anti-Cancer Therapeutic RX-3117 in the Treatment of Pancreatic and Bladder Cancer

ROCKVILLE, Md., March 29, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a ...

author_avatar
NASDAQ Market News